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AbstrAct
Objective The dual-therapy stent combines an abluminal 
biodegradable drug-eluting coating, with a ‘pro-healing’ 
luminal layer. This bioengineered layer attracts circulating 
endothelial progenitor cells that can differentiate into 
normal endothelium. Rapid endothelialisation of the stent 
might allow safe short dual antiplatelet therapy. We aim to 
assess clinical outcomes in patients treated with this novel 
device at 2-year follow-up.
Methods A total of 1000 patients were included in the 
REMEDEE Registry to evaluate clinical outcomes after 
treatment with the dual-therapy stent. This prospective, 
multicentre, European registry included all-comers 
patients, which resulted in a high-risk patient population. 
Target lesion failure (TLF), a combined endpoint consisting 
of cardiac death, target vessel myocardial infarction (tv-
MI) and target lesion revascularisation (TLR), at 2-year 
follow-up was the primary focus of this analysis. Subgroup 
analyses were performed according to diabetes mellitus 
(DM), gender, age, acute coronary syndrome, smoking, 
hypertension, hypercholesterolaemia, previous stroke, 
peripheral vascular disease and chronic renal failure.
Results TLF at 2 years was observed in 84 patients 
(8.5%), with 3.0% cardiac death, 1.2% tv-MI and 5.9% 
TLR. Definite stent thrombosis at 2 years was 0.6%. In the 
presence of DM or chronic renal failure, a higher TLF was 
observed.
Conclusions The dual-therapy stent shows favourable 
clinical outcomes from 12 months onwards. Two years 
after stent placement, low TLF and very low stent 
thrombosis rates are observed in this large prospective 
all-comers cohort study.
Trial registration number NCT01874002; Results.
IntroductIon
Innovations in the field of drug-eluting 
coronary stent (DES) therapy are rapidly 
evolving. First-generation DES improved 
outcomes in terms of reduced rates of rest-
enosis compared with bare metal stenting.1 2 
Subsequently, second-generation DES, with 
thinner stent struts, limus analogue drugs 
and more biocompatible polymers, were 
designed to reduce the increased risk of late 
clinical events of DES.3–5 The controversial 
term ‘third-generation’ DES is attributed to 
DES with newer (fully) biodegradable poly-
mers and polymer-free DES. These stents 
and also the bioabsorbable scaffolds try to 
minimise adverse outcomes.6–8 However, no 
device has been able to eliminate in-stent 
neointimal hyperplasia, neoatherosclerosis 
and/or (very) late stent thrombosis (ST).
The COMBO stent (OrbusNeich Medical, 
the Netherlands) is the first dual-therapy 
stent (DTS), which combines the ‘tradi-
tional’ drug-eluting therapy (sirolimus in a 
biodegradable polymer) with an immobil-
ised CD34 antibody that captures endothelial 
progenitor cells (EPCs) from the circulation 
(figure 1). These EPCs can differentiate into 
endothelial cells on the luminal surface of the 
stent.9 The hypothesis of this ‘pro-healing’ 
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Key messAges
What is already known about this subject? 
 ► Preclinical research showed early 
endothelialisation with this dual-therapy stent 
technology. One-year clinical results of the 1000 
patient registry have been reported with low event 
rates.
What does this study add? 
 ► There is a need for long-term clinical follow-up 
of novel coronary devices. This large prospective, 
investigator-initiated, all-comers cohort evaluates 
the real-world clinical performance of this dual-
therapy COMBO stent at 2 years after stent 
placement. Low event rates are observed at 
2-year follow-up.
How might this impact on clinical practice? 
 ► The dual-therapy stent shows good 2-year clinical 
results and might be the preferred treatment 
strategy in patients with coronary artery disease, 
and especially in patients with indication for short 
dual-antiplatelet therapy. Randomised trials are 
needed to support this hypothesis.
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Figure 1 The COMBO stent design, illustration of the dual-
therapy stent technology.
technique is that it may offer not only improved clinical 
outcomes, but also safe short use of dual-antiplatelet 
therapy (DAPT).10 11
The REMEDEE Registry (all acronyms are presented 
in the online supplementary file 1) aims to provide more 
insight into the clinical outcomes with the COMBO stent 
in routine clinical practice and in an all-comer setting. 
Currently only limited long-term data are available on 
clinical results with the COMBO DTS exceeding 1 year.12 
In this paper, we evaluate 2-year clinical results of the 
REMEDEE Registry and analyse outcomes in different 
patient subgroups.
methods
registry design and patient population 
The study design of the REMEDEE Registry 
(NCT01874002) has been previously published.13 In 
brief, the REMEDEE Registry is an investigator-initi-
ated, prospective, European registry evaluating the first 
DTS, the COMBO stent. A total of 1000 patients, in 
whom treatment with a COMBO stent in the setting of 
routine clinical care was attempted, were enrolled. DAPT 
was prescribed according to local guidelines. With only 
few exclusion criteria, a true all-comers patient popu-
lation was targeted. At 30 days, 180 days, 1-year and 
2-year follow-up, all patients were contacted for clinical 
follow-up by telephone call or during a scheduled outpa-
tient clinic visit. All event documentation was collected 
and all events were adjudicated by an independent clin-
ical event committee.
endpoints and definitions
In this 2-year follow-up analysis of the REMEDEE Registry, 
we evaluate target lesion failure (TLF), which is defined 
as the composite of cardiac death, target vessel myocar-
dial infarction (tv-MI) or target lesion revascularisation 
(TLR). Tv-MI was defined as all myocardial infarctions 
(MIs) unless in the presence of documented proof that 
the infarction arose from a non-treated coronary vessel. 
TLR was defined as any repeat revascularisation by percu-
taneous intervention of the treated lesion or coronary 
artery bypass grafting (CABG) of the treated vessel. 
Secondary endpoints were the individual components 
of the primary endpoint, target vessel failure (TVF) and 
ST at 2-year follow-up. TVF was defined the composite 
of cardiac death, tv-MI and target vessel revascularisation 
(TVR). TVR was defined as target vessel revascularisation 
(any revascularisation of the treated vessel by percuta-
neous coronary intervention (PCI) or CABG). ST was 
defined according to the Academic Research Consortium 
criteria.14
statistical analysis
Categorical data are shown with counts and percentages, 
continuous variables are in mean ± SD, unless other-
wise mentioned. For time-to-event data, Kaplan-Meier 
estimates were used for all endpoint analyses. Follow-up 
was censored at the last known date of follow-up, or at 
24 months, whichever came first. A lost to follow-up rate 
of <2% a year was deemed acceptable. All endpoints were 
evaluated in the unselected patient population, which 
consisted of all patients who were enrolled after signing an 
informed consent and in whom placement of a COMBO 
stent was attempted. Cox regression analysis was done to 
calculate HRs for diabetes mellitus (DM) status, gender, 
age, acute coronary syndrome (ACS), smoking, hyper-
tension, hypercholesterolaemia, past stroke, peripheral 
vascular disease and chronic renal failure. Statistical anal-
yses were performed using SPSS V.23.0.
results
baseline characteristics
Between June 2013 and March 2014, 1000 patients were 
enrolled in nine European sites. The baseline charac-
teristics are presented in table 1. The mean age during 
baseline procedure was 65±11 years and 26.1% of 
patients were female. At baseline, 58.0% of the patients 
had a history of hypertension and 18.4% were diabetic. 
The registry included 30.4% of patients with an urgent 
indication for PCI. TIMI flow 0 was observed in 14.5% of 
patients and thrombus was present in 15.0% of the cases. 
In two patients, the COMBO stent could not be placed. 
Mean stent length was 21.4±10.5 mm and mean diameter 
3.2±0.5 mm.
clinical outcomes
Two-year follow-up was obtained for 981 patients (98.1%). 
Events observed at 2 years after COMBO stent placement 
are listed in table 2. TLF occurred in 84 patients (8.5%), 
as illustrated in the Kaplan-Meier curve of events found in 
figure 2. Cardiac death was observed in 3.0% of patients 
(n=30), tv-MI in 1.2% (n=12) and TLR in 5.9% (n=58) 
(figure 3). In four of the five cases of very late tv-MI, 
angiography was performed which did not show ST of 
COMBO, the fifth tv-MI was in a patient presenting with 
dyspnoea and decompensatio cordis, without chest pain 
but classified as non-ST-segment elevation MI. Echocardi-
ography showed diffuse impaired LV function. Regional 
wall abnormalities could not discriminate location of MI; 
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Table 1 Baseline characteristics
Patients (n=1000)
Age (years) 65 ±11
Female 26.1
History of diabetes 18.4
Requiring insulin 6.4
History of hypertension 58.0
History of hyperlipidaemia 56.2
Family history of CAD 45.5
Current smoker 24.1
Chronic renal failure 6.1
Prior myocardial infarction 25.3
Prior percutaneous intervention 30.1
Prior CABG 6.8
Urgent indication for PCI 30.4
Lesions (n=1255)
TIMI flow 0 preprocedure 14.5
Thrombus present and thrombus aspiration 15.0 10.8
AHA/ACC lesion type B2/C 58.9
Lesion length (mm) 15.0 12–20
Reference vessel diameter (mm) 3.0 3.0–3.5
Percentage stenosis by visual estimate 90 80–99
Total stent length (mm) 21.4 ±10.5
Total stent diameter (mm) 3.2 ±0.5
Values are valid %, mean ± SD, or median (IQR).
AHA/ACC, American Heart Association/American College of 
Cardiology classification; CABG, coronary artery bypass graft; 
CAD, coronary artery disease; PCI, percutaneous coronary 
intervention. 
Table 2 Clinical endpoints at 1-year and 2-year follow-up
1-year follow-
up
Total 2-year 
follow-up
N % N %
TLF 57 5.7 84 8.5
Cardiac death 17 1.7 30 3.0
Target vessel MI 7 0.7 12 1.2
TLR 43 4.3 58 5.9
TVR 48 4.8 70 7.1
TVF 62 6.2 96 9.7
Definite ST 5 0.5 6 0.6
Probable ST 1 0.1 1 0.1
MI, myocardial infarction; ST, stent thrombosis; TLF, target lesion 
failure; TLR, target lesion revascularisation; TVF, target vessel 
failure; TVR, target vessel revascularisation.
Figure 2 Cumulative event rate of target lesion failure by 
Kaplan-Meier method.
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therefore, the CEC classified as tv-MI. Due to absence of 
ST-segment elevation on inferior leads (COMBO in right 
coronary artery), the possibility of an ST was found less 
likely by the CEC.
A total of 70 patients underwent TVR (7.1%), resulting 
in a 9.7% TVF at 2 years. Definite ST at 2 years occurred 
in six patients (0.6%). Five patients had ST within the 
first nine days post procedure, one patient with ACS had 
a very late ST at 380 days, shortly after DAPT cessation.
The influence of baseline patient characteristics 
(gender, age, cardiovascular risk factors, ACS, peripheral 
vascular disease and chronic renal failure) on 2-year clin-
ical outcome is shown in figure 4. The only significant 
univariate predictors of TLF were diabetes HR 3.00 (95% 
CI 1.93 to 4.66) and chronic renal failure HR 2.47 (95% 
CI 1.31 to 4.67), although trends were seen with current 
smokers, ACS and peripheral vascular disease.
dIscussIon And lImItAtIons
Key findings
This study reports the clinical outcomes up to 2-year 
follow-up in a large prospective, all-comers cohort of 
patients treated with the COMBO stent. We found (1) low 
rates of clinical events observed at 2 years after COMBO 
DTS implantation with an overall low percentage of the 
primary endpoint TLF of 8.5% and very late ST in only 
one patient (0.1%), (2) our subgroup analyses found 
that the COMBO DTS gave favourable results in several 
high-risk patient groups although higher rates of TLF 
were observed at 2 years in patients with DM and chronic 
renal failure higher rates of TLF,and (3) the rate of TLR 
between 1 and 2 years follow-up was very low.
clinical implications
Currently only limited data are available on clinical 
outcomes with the COMBO DTS exceeding 1-year 
follow-up.12 The results presented in this study are in line 
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Figure 3 Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. 
(A) Cumulative event rate of the individual endpoint cardiac death. (B) Cumulative event rate of the individual endpoint target 
vessel-related MI. (c) Cumulative event rate of the individual endpoint TLR.
Figure 4 Subgroups. HR of gender, age, diabetic 
status, smoking (current and previous), hypertension, 
hypercholesterolaemia, chronic renal failure, previous stroke, 
peripheral vascular disease and acute coronary syndrome 
(ACS) on target lesion failure at 2-year follow-up. PCI, 
percutaneous coronary intervention
Figure 5 Comparison of target vessel failure at 2-year 
follow-up with other drug eluting stents (DES). DTS, dual-
therapy stent; EES, everolimus-eluting stent; PES, paclitaxel-
eluting stent; ZES, zotarolimus-eluting stent.
with other newer-generation DES (see figure 5) such as 
the all-comers TWENTE15 and RESOLUTE (see online 
supplementary file 1)16 trials which compared a zotar-
olimus-eluting stent (ZES) (RESOLUTE, Medtronic, 
USA) with an everolimus-eluting stent (EES) (XIENCE 
V, Abbott Vascular, USA). In addition, compared with 
the 2-year outcomes of the more selected patient popu-
lation SPIRIT IV trial, comparing a paclitaxel-eluting 
stent (PES) (TAXUS, Boston Scientific, USA) with an 
EES (XIENCE, Abbott Vascular, USA), reported similar 
outcomes.17
ST in the REMEDEE Registry was reassuringly low 
despite the all-comers design. In particular, very late 
ST (between 12 and 24 months) occurred in only 0.1% 
of patients receiving the COMBO stent (which is lower 
than with the other devices above; EES varies 0.1–0.3, 
ZES 0.3% and PES 0.2%).15–17 A recent meta-analysis by 
Nairooz et al reports a 2-year ST rate of the bioresorbable 
vascular scaffold of 2.1%.18 The low ST rate at 2 years with 
the COMBO stent is a significant finding supporting the 
DTS technology hypothesis of low ST risk due to early 
endothelialisation of the stent, but caution should be 
taken and randomised data are needed to confirm these 
findings.
neointimal regression
A recent study evaluating the healing pattern of the 
COMBO stent at 4-monthly groups (1:2:2:1 ratio from 
2 to 5 months), 9 months and 24 months showed a 
new phenomenon not described earlier with any other 
DES: neointimal regression visualised by optical coher-
ence tomography between 9 and 24 months.12 This 
intimal hyperplasia regression has also been assessed by 
quantitative coronary analyses previously in the Genous 
stent (OrbusNeich, a BMS with EPC capturing layer).19 
These consistent findings may support the hypothesis 
of the beneficial effect of rapid endothelialisation and 
healthy maturation of the endothelial layer by means of 
EPC capture by the immobilised CD34 antibody at the 
stent surface. This study showed low TLR rate between 1 
and 2 years (from 4.3% to 5.9%; a 1.6% increase). More-
over, these results emphasise the need for evaluation of 
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long-term clinical results, exceeding 1-year follow-up, to 
make the true comparison of performance of the DES.
subgroups
DM is a known risk factor for higher adverse outcome 
after PCI.20 21 We published 1-year clinical outcomes after 
COMBO stent placement of insulin-treated DM, non-in-
sulin-treated DM and non-DM patients, with a clear signal 
of higher TLF in insulin-treated DM.22 Although patients 
with chronic kidney disease (CKD) often have DM, after 
multiple regression analyses in the DM group at 1 year, 
CKD was also independently associated with higher TLF. 
Clinical outcomes of patients with CKD and stent place-
ment should further be explored.
Future perspectives
The REMEDEE Registry will evaluate patients up to 5 
years after COMBO stent placement, and thereby, will 
give further insight into the long-term treatment effect of 
DTS technology with COMBO. Currently the US–Japan 
randomised HARMONEE trial (see online supplemen-
tary file 1), which evaluates clinical outcomes between 
EES (XIENCE family, Abbott Vascular) versus COMBO, 
awaits completion of 1-year follow-up. This study will also 
obtain clinical follow-up up to 5 years too.
limitations
The main limitation of the REMEDEE Registry was the 
single-arm design. However, data collection was under-
taken with great care to ensure optimum data quality. 
On-site monitoring and full-event documentation were 
collected for independent adjudication by the clinical 
event committee. Another limitation of the registry 
design is that the DAPT duration was not mandated by 
the registry’s protocol; therefore, the majority of patients 
received DAPT for 1 year. A potential benefit of the 
COMBO DTS would be illustrated more clearly if a short 
duration of DAPT (eg, <6 months) after COMBO stent 
placement would show the same low ST rates. However, 
this study is the first large cohort to report on long-term 
results after COMBO stent in an all-comer patient popu-
lation and provides new insight into the performance of 
DTS.
conclusIon
Two-year clinical results with the COMBO stent in the 
1000 subject REMEDEE Registry have shown low rates of 
TLF, TVF and ST. These results confirm the long-term 
clinical effectiveness of DTS technology in an all-comers 
patient population.
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